Compare ResMed Inc. (RMD) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Smith & Nephew plc — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: ResMed Inc. is far larger — about 2.9× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Smith & Nephew plc for 121 Days on average.
| RMD | SNN | |
|---|---|---|
Market Cap | $31.89B | $11.10B |
Volume | 618,314 | 1,051,703 |
Sector | Health | Health |
52-Week High | $275.96 | $37.17 |
52-Week Low | $182.82 | $26.42 |
Typical Hold Time | 51 Days | 121 Days |
Enterprise Value | $31.24B | $14.13B |
Dividend Yield | 1.16% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $226.73, up 0.33% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming Q1 2027 earnings report and management's focus on 12%-14% EPS growth driven by demand in sleep therapy.
The outlook for RMD is positive, supported by robust fundamentals and analyst consensus, though risks include competitive pressures and ongoing legal investigations. Upside potential exists with a consensus price target of $242.70, representing a 7% increase from current levels, but investors should monitor execution against growth targets and market share dynamics.
Smith+Nephew (SNN) trades at $26.96, near its 52-week low, with bearish technical signals despite recent earnings beats. The company shows strong fundamentals with revenue growth to $6.16B in 2025 and improving profit margins of 10.08%. Recent product launches in trauma care and surgical robotics highlight innovation, but analyst sentiment remains cautious with 65% hold ratings.
Investment outlook is mixed: solid fundamentals and product pipeline offer upside, but technical weakness and analyst skepticism pose near-term risks. Key catalysts include execution on new product adoption and margin expansion, while risks involve competitive pressures and leadership transitions following the CFO's departure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
